Opening the book…
Discovery can start with a clue about how a disease works. If a disease involves an overactive receptor, for example, researchers might look for a compound that blocks it. They may search collections of compounds, study substances from natural sources, or design candidates around a specific target.
High-throughput screening (HTS) uses automated methods to evaluate many
compounds or biological candidates efficiently. A positive screening result identifies a possible lead, not a proven medicine. Researchers must confirm the result and examine selectivity, activity, safety, and other properties.
During nonclinical development, researchers study the candidate’s activity and safety using suitable laboratory systems, computer models, and animal studies where appropriate. They also develop the formulation, the manufacturing process, and tests for properties such as identity, purity, potency, and stability.
Nonclinical studies help characterize biological activity, toxicity, and how a candidate moves through the body. Appropriate studies can examine:
Absorption — How the substance enters the bloodstream from the administration site.
Distribution — How it moves into tissues and body fluids.
Metabolism — How the body changes the substance and what metabolites are formed.
Excretion — How the substance and its metabolites leave the body.
Together, these processes are called ADME. They help explain what happens to a drug in the body over time. Toxicology looks at the harm a candidate might cause. A toxicologist may use ADME data to help interpret why an effect occurs at a particular dose.
For covered U.S. studies, the sponsor generally submits an investigational new drug application (IND). The submission describes the relevant nonclinical findings, how the study material will be made and controlled, and how the study will be run, including plans to protect participants.
Making a Consistent Supply for Studies
As the studies progress, the manufacturing team needs to know how each supply of study material was made. A change in formulation, production scale, or storage can affect the material. Comparing supplies helps the team judge whether results from earlier studies still apply.
Imagine a team developing a therapeutic enzyme made by cultured cells. Early experiments may need only a small amount. A clinical trial needs enough material for participants, with records showing its identity, quality, and handling. Commercial production may require many batches. In a larger vessel, the cells may experience different mixing or temperature conditions, so the team checks whether the enzyme still meets its specifications.
Quality assurance (QA) focuses on the systems used to plan and control work. Examples include approved procedures, training, supplier oversight, change control, and investigation processes. Quality control (QC) includes activities such as sampling, testing, and evaluating results against established criteria. QA and QC support one another throughout development and production.
In the enzyme example, the quality assurance team helps ensure that staff have the approved procedure and the training to follow it. Quality control staff test the enzyme against established criteria. If a result falls outside a specification, the team investigates the result and the process. Continuous improvement uses those findings to strengthen controls and checks whether the changes work.
A sponsor may hire a contract research organization (CRO) to carry out research activities or a contract development and manufacturing organization (CDMO) to develop a process or make the product. The parties need to define who will do each task and how the work will be overseen. Any transfer of sponsor obligations to a CRO under the IND regulations must be described in writing.
This page titled 12.2: Discovery and Nonclinical Development was last modified on Sun, 08 Nov 2026 13:54:15 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.